189 related articles for article (PubMed ID: 21175792)
1. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
Yoon H; Kim N; Kim JY; Park SY; Park JH; Jung HC; Song IS
J Gastroenterol Hepatol; 2011 Jan; 26(1):44-8. PubMed ID: 21175792
[TBL] [Abstract][Full Text] [Related]
2. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication.
Kim MN; Kim N; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Kim JS; Jung HC; Song IS
Helicobacter; 2008 Aug; 13(4):261-8. PubMed ID: 18665934
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection.
Du YQ; Su T; Fan JG; Lu YX; Zheng P; Li XH; Guo CY; Xu P; Gong YF; Li ZS
World J Gastroenterol; 2012 Nov; 18(43):6302-7. PubMed ID: 23180952
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
Yoon H; Kim N; Lee BH; Hwang TJ; Lee DH; Park YS; Nam RH; Jung HC; Song IS
Helicobacter; 2009 Oct; 14(5):77-85. PubMed ID: 19751431
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
8. Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial.
Tongtawee T; Dechsukhum C; Leeanansaksiri W; Kaewpitoon S; Kaewpitoon N; Loyd RA; Matrakool L; Panpimanmas S
Asian Pac J Cancer Prev; 2015; 16(12):4885-90. PubMed ID: 26163609
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
[TBL] [Abstract][Full Text] [Related]
10. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Grgov S; Tasić T; Radovanović-Dinić B; Benedeto-Stojanov D
Vojnosanit Pregl; 2016 Nov; 73(11):1044-9. PubMed ID: 29328644
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy.
Sheu BS; Cheng HC; Kao AW; Wang ST; Yang YJ; Yang HB; Wu JJ
Am J Clin Nutr; 2006 Apr; 83(4):864-9. PubMed ID: 16600940
[TBL] [Abstract][Full Text] [Related]
13. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
Miehlke S; Krasz S; Schneider-Brachert W; Kuhlisch E; Berning M; Madisch A; Laass MW; Neumeyer M; Jebens C; Zekorn C; Knoth H; Vieth M; Stolte M; Lehn N; Morgner A
Helicobacter; 2011 Dec; 16(6):420-6. PubMed ID: 22059392
[TBL] [Abstract][Full Text] [Related]
16. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
Ciccaglione AF; Cellini L; Grossi L; Marzio L
World J Gastroenterol; 2012 Aug; 18(32):4386-90. PubMed ID: 22969203
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation.
Efrati C; Nicolini G; Cannaviello C; O'Sed NP; Valabrega S
World J Gastroenterol; 2012 Nov; 18(43):6250-4. PubMed ID: 23180945
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Apr; 21(16):5032-8. PubMed ID: 25945019
[TBL] [Abstract][Full Text] [Related]
19. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Kiliç ZM; Köksal AS; Cakal B; Nadir I; Ozin YO; Kuran S; Sahin B
Dig Dis Sci; 2008 Dec; 53(12):3133-7. PubMed ID: 18465244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
